Homologous
Recombination
Deficiency (HRD)
PRODUCT DESCRIPTION
NGS panel to assess the status of HRD through the detection of BRCA1/2 gene mutation AND determination of the genomic instability. HRD status has prognostic and therapeutic implications that are important to identify the magnitude of benefit of PARP inhibitors during treatment planning.
HIGHLIGHTED GENES
BRCA1, BRCA2, and genomic instability (LOH: Loss of heterozygosity, LST: Large-scale state transitions, and TAI: Telomeric-allelic imbalance markers).
NCCN RECOMMENDS HRD TESTING FOR
Ovarian, fallopian tube and primary peritoneal cancers.